undamentalytics Newsletter
Sign in

Black Diamond Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Black Diamond Therapeutics, Inc. had total assets of $143m, total liabilities of $30.8m and shareholders' equity of $112m. It held $21.0m in cash against $0 of debt: net cash of $21.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents5215535362119
Total current assets52156320101132115
Total assets52158330123143125
Accounts payable023411
Total current liabilities3514211616
Total debt000000
Total liabilities7522393129
Shareholders' equity−16−473088311296
Non-controlling interests and other (assets − liabilities − equity)61201————
Net debt (negative = net cash)−52−155−35−36−21−19
Shares outstanding33m34m36m57m57m57m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Black Diamond Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Black Diamond Therapeutics, Inc.